or Try an Advanced Search...

    Anti Diabetic Drugs Stocks List

    Symbol Grade Name % Change
    TERN D Terns Pharmaceuticals, Inc. 1.17
    NVO F Novo Nordisk A/S -0.01
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Obesity Peptide Hormones Bile Acid Chronic Liver Diseases Diabetes Diabetes Care Endocrine System Glucagon Glucagon Like Peptide 1 Growth Hormone Growth Hormone Therapy Haemophilia Hepatitis Hormone Therapy Hormones Inflammation Insulin Life Sciences Liver

    Related ETFs - A few ETFs which own one or more of the above listed Anti Diabetic Drugs stocks.

    Symbol Grade Name Weight
    EDEN D iShares MSCI Denmark Capped ETF 22.75
    OZEM D Roundhill GLP-1 & Weight Loss ETF 19.61
    THNR F Amplify Weight Loss Drug & Treatment ETF 13.58
    PPH D Market Vectors Pharmaceutical ETF 8.32
    PJIO D PGIM Jennison International Opportunities ETF 6.5
    View all Anti Diabetic Drugs ETFs...
    Compare ETFs
    Compare EDEN to PJIO Compare OZEM to PPH Compare THNR to PPH

        Anti Diabetic Drugs Stocks Recent News

        Date Stock Title
        Nov 1 NVO Election Day, Fed decision, earnings: What to Watch Next Week
        Nov 1 NVO Why iShares’ Europe ETF (IEUR) May Be Attractive for U.S. Investors
        Nov 1 NVO Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
        Nov 1 NVO Novo Nordisk's Semaglutide Trial Shows 'Superior Improvement' in Liver Fibrosis, MASH
        Nov 1 NVO Novo Nordisk Says Wegovy Improved Patients’ Liver Disease
        Nov 1 NVO Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
        Nov 1 NVO Novo Nordisk posts Phase 3 win for obesity drug in MASH
        Nov 1 NVO Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
        Nov 1 NVO Novo, with new results, to seek approval for obesity drug in MASH
        Oct 31 NVO Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
        Oct 30 NVO Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
        Oct 30 NVO Eli Lilly plans to begin advertising weight-loss drug Zepbound
        Oct 30 NVO Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks
        Oct 30 NVO Novo takes big step toward ending Ozempic, Wegovy shortages
        Oct 30 NVO Eli Lilly drops, sending Novo lower after Q3 miss
        Oct 30 NVO Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations
        Oct 30 NVO Eli Lilly Stock Tumbles as Q3 Sales, Profits Fall Well Short of Estimates
        Oct 30 NVO The Zacks Analyst Blog Apple, Novo Nordisk, RTX and FONAR
        Oct 30 NVO Lilly shares fall as obesity drug sales miss forecasts
        Oct 29 NVO Key Novo Nordisk plant where Wegovy, Ozempic made cited by FDA
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Obesity Peptide Hormones Bile Acid Chronic Liver Diseases Diabetes Diabetes Care Endocrine System Glucagon Glucagon Like Peptide 1 Growth Hormone Growth Hormone Therapy Haemophilia Hepatitis Hormone Therapy Hormones Inflammation Insulin Life Sciences Liver
        Anti Diabetic Drugs

        Anti-diabetic drugs are medications used to treat people with diabetes mellitus. They work by either increasing the amount of insulin produced by the body, or by helping the body use the insulin it produces more effectively. Common types of anti-diabetic drugs include insulin, sulfonylureas, biguanides, thiazolidinediones, meglitinides, and alpha-glucosidase inhibitors.

        Browse All Tags